<DOC>
	<DOC>NCT01095393</DOC>
	<brief_summary>Observational registry to assess the longer-term risk of serious infections and malignancies reported with TNFα-blocker therapy, as well as the longer-term risk of cardiovascular and thromboembolic events in adult Rheumatoid Arthritis (RA) patients treated with Cimzia® as compared to non-biologic DMARD-treated controls.</brief_summary>
	<brief_title>National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>RA and started treatment with certolizumab pegol (Cimzia®; CZP) or nonbiologic DMARD within the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>CZP</keyword>
	<keyword>Cimzia®</keyword>
	<keyword>NDB</keyword>
	<keyword>registry</keyword>
</DOC>